Meta- analysis of RCTs showed that only cyclosporine A provided a simultaneous great effect size of SMD on ICSI , pain , and frequency .
Amitriptyline at different dosages showed a great effect size of SMD on pain and urgency or on ICSI and frequency .
The results from the n RCTs showed that the most frequently adopted treatment is oral pentosan polysulfate and that the use of botulinum A toxin intradetrusorial injections in PBS/IC is increasing .
Limited evidence exists for the few treatments for PBS/IC .
The lack of definitive conclusions is due to the great heterogeneity in methodology , symptoms assessment , duration of treatment , and follow-up in both RCTs and n RCTs
CONTEXT Different types of behavioural , dietary , interventional , pharmacologic , and surgical therapies have been used to treat painful bladder syndrome/interstitial cystitis ( PBS/IC ) .
Because of the paucity of r and omised placebo-controlled studies on different treatments , an evidence -based management approach has not yet been developed .
OBJECTIVE To critically review and synthesize data from a wide range of current therapeutic approaches to PBS/IC , to quantify the effect size from r and omised controlled trials ( RCTs ) , and to reach clinical agreement on the efficacy of treatments for PBS/IC .
Improvement of interstitial cystitis symptoms and problems that developed during treatment with oral IPD-1151T.
PURPOSE We examined the efficacy of Suplatast Tosilatedouble dagger ( IPD-1151 T ) , a new immunoregulator that suppresses helper T cell mediated allergic responses , including IgE production and eosinophilic inflammation for treating patients with interstitial cystitis . MATERIAL S AND METHODS A total of 14 women ( average age 43.7 years ) with interstitial cystitis , which was nonulcerative in 13 and ulcerative in 1 , were treated with 300 mg . IPD-1151 T orally daily for 12 months . All patients received laboratory assessment s , including hematology ( eosinophils and CD20 positive cells ) and serum chemistry ( IgE , and interleukin-4 ( IL-4 ) and 5 , and immunohistochemical analyses of urine leukocytes ( CD45RO positive cells as a T cell marker ) before treatment . These parameters were also measured 4 and 12 months after continuous treatment . The voiding chart , and interstitial cystitis symptom and problem indexes were evaluated before and after IPD-1151 T treatment . RESULTS IPD-1151 T treatment for 1 year result ed in a significantly increased bladder capacity and decreased symptoms , such as urinary urgency , frequency and lower abdominal pain , in patients with nonulcerative interstitial cystitis . These effects also correlated with a reduction in blood eosinophils , CD20 positive cells and IgE , and urine CD45RO positive memory T cells . No major side effects were observed . CONCLUSIONS Our study suggests that immunological responses are involved in the development of interstitial cystitis symptoms . IPD-1151 T could be a new oral agent for treatment of voiding symptoms and bladder pain in patients with interstitial cystitis
Meta- analysis of RCTs showed that only cyclosporine A provided a simultaneous great effect size of SMD on ICSI , pain , and frequency .
Amitriptyline at different dosages showed a great effect size of SMD on pain and urgency or on ICSI and frequency .
The results from the n RCTs showed that the most frequently adopted treatment is oral pentosan polysulfate and that the use of botulinum A toxin intradetrusorial injections in PBS/IC is increasing .
Limited evidence exists for the few treatments for PBS/IC .
The lack of definitive conclusions is due to the great heterogeneity in methodology , symptoms assessment , duration of treatment , and follow-up in both RCTs and n RCTs
CONTEXT Different types of behavioural , dietary , interventional , pharmacologic , and surgical therapies have been used to treat painful bladder syndrome/interstitial cystitis ( PBS/IC ) .
Because of the paucity of r and omised placebo-controlled studies on different treatments , an evidence -based management approach has not yet been developed .
OBJECTIVE To critically review and synthesize data from a wide range of current therapeutic approaches to PBS/IC , to quantify the effect size from r and omised controlled trials ( RCTs ) , and to reach clinical agreement on the efficacy of treatments for PBS/IC .